Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 保健營養系(所) > 期刊論文 > Item 310902800/34654

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34654

標題:	Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
作者:	Lee, Mei-Chuan Hua, Yi-Ming Yang, Chun-Ting Kuo, Fang-Hsiu Chang, Wei-Ting Tang, Hsin-Ju Toh, Han Siong Lin, Yu-Min Chen, Sih-Yao Chang, Hung-Yu Liao, Chia-Te
貢獻者:	Chi Mei Hospital National Cheng Kung University National Cheng Kung University Chi Mei Hospital National Cheng Kung University Southern Taiwan University of Science & Technology Chang Gung University of Science & Technology Chi Mei Hospital Department of Health and Nutrition, Chia Nan University of Pharmacy & Science National Yang Ming Chiao Tung University Cheng Hsin General Hospital
關鍵字:	cotransporter 2 inhibitors empagliflozin risk
日期:	2022
上傳時間:	2023-12-11 14:03:09 (UTC+8)
出版者:	LIPPINCOTT WILLIAMS & WILKINS
摘要:	Background:Some sodium-glucose co-transporter-2 (SGLT2) inhibitors showed benefits on heart failure (HF), but different SGLT2/SGLT1 selectivity might influence the treatment effect. This study aimed to meta-analyze the treatment effects of SGLT2 inhibitors and the diversity of receptor selectivity for patients with and without HF. Methods:Randomized controlled trials were searched in PubMed, Embase, Cochrane databases and ClinicalTrials.gov registry from inception to October 2020. The interest outcomes were analyzed with random-effects models and presented with a risk ratio (RR) and 95% confidence interval (CI). Subgroup analyses examined the treatment effects among SGLT2 inhibitors with different SGLT2/SGLT1 selectivity. Results:The final analyses included 10 trials and 52,607 patients. The RR of total cardiovascular (CV) death or hospitalization for HF (HHF) between SGLT2 inhibitors and placebo was 0.79 (95% CI 0.74-0.84, I-2 = 31%). With SGLT2 inhibitors, HF patients had reduced mortality risks (RR 0.89, 95% CI 0.80-0.99, I-2 = 0), and non-HF patients had lower risks of major adverse CV events (RR 0.92, 95% CI 0.85-0.99, I-2 = 0). The risk reduction of HHF was consistent in groups of HF (RR 0.72, 95% CI 0.64-0.80, I-2 = 8%) and non-HF (RR 0.74, 95% CI 0.61-0.89, I-2 = 0), but the effect of the low SGLT2/SGLT1 selectivity inhibitor was insignificant in non-HF patients. Conclusion:The efficacy of SGLT2 inhibitors on risk reduction of total CV death or HHF is consistent with the previous studies. The regimen is beneficial for reducing mortality in patients with HF and major adverse CV events in those without HF. Different SGLT2/SGLT1 selectivity may differ in the treatment effects in patients with and without HF.
關聯:	MEDICINE, v.101, n.51, e32489
显示于类别:	[保健營養系(所) ] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	169	检视/开启
MD.0000000000032489.pdf		1555Kb	Adobe PDF	77	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....